Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Gemcitabine in LMS and UPS
NCT03123276Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2017
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), sponsored by Royal Marsden NHS Foundation Trust. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
leiomyosarcoma (LMS)undifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT03123276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123276.